What is pulmonx?
Pulmonx Corporation is a commercial-stage medical technology leader dedicated to transforming the treatment landscape for severe emphysema. Its core value proposition centers on the Zephyr Endobronchial Valve, an FDA-approved implantable device engineered to reduce lung hyperinflation by collapsing diseased lung segments. This minimally invasive approach is supported by a robust diagnostic ecosystem, including the Chartis Pulmonary Assessment System and the StratX/LungTraX platforms, which utilize advanced imaging to optimize patient selection. With a global footprint exceeding 40,000 treated patients, the company maintains a dominant market position by bridging the gap between traditional medical management and invasive surgical procedures.
How much funding has pulmonx raised?
pulmonx has raised a total of $421.1M across 10 funding rounds:
Series A
$7.1M
Series B
$20M
Series C
$32M
Series D
$10M
Private Equity
$10M
Debt
$20M
Private Equity
$50M
Multiple Rounds
$272M
Series A (2003): $7.1M with participation from MedVenture Associates and Montreux Equity Partners
Series B (2007): $20M led by Montreux Equity Partners, DeNovo Ventures, MedVenture Associates, and Latterell Venture Partners
Series C (2010): $32M supported by Healthcap Venture Capital, Kleiner Perkins Caufield & Byers, Montreux Equity Partners, MedVenture Associates, De Novo Ventures, and Latterell Venture Partners
Series D (2012): $10M, investors not publicly disclosed
Private Equity (2014): $10M, investors not publicly disclosed
Debt (2014): $20M with participation from Oxford Finance, LLC
Private Equity (2015): $50M, investors not publicly disclosed
Debt (2020): $65M supported by ADAGE CAPITAL MANAGEMENT LP, Ally Bridge Group, HealthQuest Capital, Rock Springs Capital LLC, and Partner Fund Management , L.P.
Debt (2020): $17M featuring CIBC
Stock Issuance/Offering (2020): $190M, investors not publicly disclosed
Key Investors in pulmonx
Healthcap Venture Capital
A life science investor and company creator focused on innovative healthcare solutions, targeting rare diseases and high unmet medical needs through sustainable investment strategies.
Kleiner Perkins Caufield & Byers
A prominent Menlo Park-based venture capital firm that provides operational support and capital to early and growth-stage companies across the healthcare and technology sectors.
Ally Bridge Group
A global healthcare investment management firm specializing in high-impact life science innovation, managing significant transactions to address unmet medical needs through scientific and financial expertise.
What's next for pulmonx?
Looking ahead, Pulmonx is positioned to leverage its recent capital influx to accelerate market penetration and further refine its diagnostic planning tools. The strategic focus remains on expanding the clinical adoption of its interventional pulmonology solutions, particularly in under-served global markets. As the company continues to mature, the integration of its diagnostic and therapeutic platforms will likely serve as a primary driver for sustained growth, enabling more precise patient outcomes and reinforcing its leadership in the respiratory health space. Future initiatives will likely prioritize clinical evidence generation and the expansion of its commercial infrastructure to meet the rising demand for non-surgical COPD interventions.
See full pulmonx company page
